Inhibition of P-glycoprotein-Mediated Efflux of Anthracyclines by Ionophores
Author Information
Author(s): Marie-Nicole Borrel, Elene Pereira, Marina Fiallo, Arlette Garnier-Suillerot
Primary Institution: Laboratoire de Chimie Bioinorganique, LPCB (URA CNRS 198), Université de Paris Nord
Hypothesis
Can ionophores inhibit the P-glycoprotein-mediated efflux of anthracyclines in resistant cancer cells?
Conclusion
Ionophores can inhibit the efflux of anthracyclines by P-glycoprotein, potentially reversing multidrug resistance in cancer cells.
Supporting Evidence
- Ionophores like valinomycin and nigericin were found to inhibit the efflux of anthracyclines.
- The study showed that ionophores can increase drug accumulation in resistant cells.
- Cyclosporin A, a known MDR reversing agent, also inhibited P-glycoprotein-mediated efflux.
Takeaway
Some special molecules called ionophores can help cancer drugs stay inside cells longer, which might help fight cancer better.
Methodology
The study developed a method to follow the uptake of fluorescent drugs in living cells to analyze the effect of ionophores on drug accumulation.
Limitations
The exact mechanisms by which ionophores affect drug resistance are not fully understood.
Participant Demographics
The study involved drug-sensitive and resistant K562 erythroleukemia cell lines.
Want to read the original?
Access the complete publication on the publisher's website